Compile Data Set for Download or QSAR
Report error Found 43 Enz. Inhib. hit(s) with all data for entry = 831
TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293963BDBM293963(US10106552, Compound 38)
Affinity DataIC50: 300nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293960BDBM293960(US10106552, Compound 35)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293961BDBM293961(US10106552, Compound 36)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293965BDBM293965(US10106552, Compound 40)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293953BDBM293953(US10106552, Compound 28)
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293966BDBM293966(US10106552, Compound 41)
Affinity DataIC50: 500nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293954BDBM293954(US10106552, Compound 29)
Affinity DataIC50: 700nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293959BDBM293959(US10106552, Compound 34)
Affinity DataIC50: 800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293950BDBM293950(US10106552, Compound 25)
Affinity DataIC50: 800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293943BDBM293943(US10106552, Compound 18)
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293962BDBM293962(US10106552, Compound 37)
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293968BDBM293968(US10106552, Compound 43)
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293935BDBM293935(US10106552, Compound 10)
Affinity DataIC50: 1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293951BDBM293951(US10106552, Compound 26)
Affinity DataIC50: 1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293942BDBM293942(US10106552, Compound 17)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293958BDBM293958(US10106552, Compound 33)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293927BDBM293927(US10106552, Compound 2)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293944BDBM293944(US10106552, Compound 19)
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293931BDBM293931(US10106552, Compound 6)
Affinity DataIC50: 1.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293964BDBM293964(US10106552, Compound 39)
Affinity DataIC50: 1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293949BDBM293949(US10106552, Compound 24)
Affinity DataIC50: 1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293952BDBM293952(US10106552, Compound 27)
Affinity DataIC50: 1.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293932BDBM293932(US10106552, Compound 7)
Affinity DataIC50: 1.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293946BDBM293946(US10106552, Compound 21)
Affinity DataIC50: 2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293948BDBM293948(US10106552, Compound 23)
Affinity DataIC50: 2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293945BDBM293945(US10106552, Compound 20)
Affinity DataIC50: 2.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293934BDBM293934(US10106552, Compound 9)
Affinity DataIC50: 2.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293940BDBM293940(US10106552, Compound 15)
Affinity DataIC50: 2.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293926BDBM293926(US10106552, Compound 1)
Affinity DataIC50: 2.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293967BDBM293967(US10106552, Compound 42)
Affinity DataIC50: 3.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293955BDBM293955(US10106552, Compound 30)
Affinity DataIC50: 3.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293956BDBM293956(US10106552, Compound 31)
Affinity DataIC50: 3.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293957BDBM293957(US10106552, Compound 32)
Affinity DataIC50: 3.80E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293941BDBM293941(US10106552, Compound 16)
Affinity DataIC50: 4.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293933BDBM293933(US10106552, Compound 8)
Affinity DataIC50: 4.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293937BDBM293937(US10106552, Compound 12)
Affinity DataIC50: 5.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293930BDBM293930(US10106552, Compound 5)
Affinity DataIC50: 6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293947BDBM293947(US10106552, Compound 22)
Affinity DataIC50: 6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293936BDBM293936(US10106552, Compound 11)
Affinity DataIC50: 2.30E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293938BDBM293938(US10106552, Compound 13)
Affinity DataIC50: 3.10E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293939BDBM293939(US10106552, Compound 14)
Affinity DataIC50: 5.02E+6nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293928BDBM293928(US10106552, Compound 3)
Affinity DataIC50: 1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetEukaryotic elongation factor 2 kinase(Human)
Longevica Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 293929BDBM293929(US10106552, Compound 4)
Affinity DataIC50: 1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent